What question did this study set out to answer?

This study aims to determine if clonal hematopoiesis of indeterminate potential (CHIP) predicts adverse outcomes in patients with established atherosclerotic cardiovascular disease (ASCVD).

May 21, 2026Journal of the American College of CardiologyOpen Access

Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease

Q: What are the key findings of this study?

Any CHIP was associated with an increased risk of ASCVD events and all-cause mortality in patients with established ASCVD (HR 1.23; 95% CI 1.10-1.38; P<0.001).

Q: What is the clinical evidence from this study?

Study design: Cohort. Population: Atherosclerotic cardiovascular disease (ASCVD) (n=13129). Intervention: Clonal hematopoiesis of indeterminate potential (CHIP) vs. No CHIP. Primary outcome: Composite of ASCVD events and all-cause mortality (HR 1.23, 95% CI 1.10-1.38, p=< 0.001).

View Full Paper

Ask AI

Bookmark

Key result

Any CHIP linked to ~23% higher risk of ASCVD events and mortality in established ASCVD.

HR 1.23
95% CI 1.10-1.38
P<0.001
n=13,129

Key Points

This study aims to determine if clonal hematopoiesis of indeterminate potential (CHIP) predicts adverse outcomes in patients with established atherosclerotic cardiovascular disease (ASCVD).
Analyzed individuals aged 40 to 70 from the UK Biobank with ASCVD and available whole-exome sequences.
Compared outcomes in individuals with any CHIP and large CHIP clones using unadjusted and multivariable-adjusted Cox regression.
Primary outcome was a composite of ASCVD events and all-cause mortality.
5.1% of individuals had CHIP, with adjusted HRs of 1.23 (95% CI: 1.10-1.38; P < 0.001) for any CHIP and 1.34 (95% CI: 1.17-1.53; P < 0.001) for large CHIP.
Large TET2 CHIP had an HR of 1.89 (95% CI: 1.40-2.55; P <0.001) and large spliceosome CHIP had HR of 3.02 (95% CI: 1.95-4.70; P < 0.001), indicating particularly high risks.

Study Design

Type

Cohort (n=13,129)

PICO

Population

Atherosclerotic cardiovascular disease (ASCVD) (n=13,129)

Intervention / Comparator

Clonal hematopoiesis of indeterminate potential (CHIP) vs No CHIP

Primary Outcome

Composite of ASCVD events and all-cause mortality — HR 1.23 (1.10-1.38), p=< 0.001

Main Result

Effect estimate: HR 1.23 (95% CI 1.10-1.38)

p-value: p=< 0.001

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

CHIP may refine prognostication in established ASCVD; leaves open whether targeting CHIP improves outcomes.

Cite This Study

Gümüşer et al. (2023) conducted a cohort in Atherosclerotic cardiovascular disease (ASCVD) (n=13,129). Clonal hematopoiesis of indeterminate potential (CHIP) vs. No CHIP was evaluated on Composite of ASCVD events and all-cause mortality (HR 1.23, 95% CI 1.10-1.38, p=< 0.001). Any CHIP was associated with an increased risk of ASCVD events and all-cause mortality in patients with established ASCVD (HR 1.23; 95% CI 1.10-1.38; P<0.001).

synapsesocial.com/papers/6a0f76cc91e834c62cd8a5cb https://doi.org/10.1016/j.jacc.2023.03.401

View Full Paper

Ask AI

Bookmark

Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease

Key Points

Study Design

PICO

Main Result

Discussion

Implication

Cite This Study

Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease

Key Points

Study Design

PICO

Main Result

Discussion

Implication

Cite This Study

Also Consider

Also Consider